Influenza viruses are characterized by two surface glycoproteins i.e. hemagglutinnin and neuraminidase. Neuraminidase are the antigens which play an important role in defining the particular strain of influenza. Dosage and safety of neuraminidase inhibitors are the two main parameters, affecting the growth of neuraminidase inhibitors market. The various symptoms of influenza are cough, running nose, fever, headache, fatigue, chills etc. The neuraminidase are recommended for the treatment of the symptoms after the forty eight hours of start of these symptoms.
There are few neuraminidase inhibitors, being sold in the market. The neuraminidase inhibitors have been classified as zenamivir, oseltamivir, peramivir, leninamivir and few other neuraminidase inhibitors. Zenamivir and oseltamivir are the neuraminidase inhibitors which are being used for the treatment of influenza A or influenza B.

Market Analysis and Insights: Global Neuraminidase Inhibitor Market
The global Neuraminidase Inhibitor market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Neuraminidase Inhibitor Scope and Market Size
The global Neuraminidase Inhibitor market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuraminidase Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Zanamivir
Oseltamivir
Peramivir
Laninamivir

Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others

The Neuraminidase Inhibitor market is analysed and market size information is provided by regions (countries). Segment by Application, the Neuraminidase Inhibitor market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
BioCryst
Daiichi Sankyo